

Purified Cortrophin Gel® (repository corticotropin injection)

When requesting Purified Cortrophin Gel® (repository corticotropin injection), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines.

FDA-approved Indications

Purified Cortrophin Gel is indicated in the following disorders:

- Rheumatic disorders;
- Collagen diseases;
- Dermatologic diseases;
- Allergic states;
- Ophthalmic diseases;
- Respiratory diseases;
- Edematous states;
- Nervous system;

Coverage Guidelines

Due to the lack of updated clinical efficacy data and potential safety concerns with long-term use, approval is not recommended for Purified Cortrophin Gel. The current Purified Cortrophin Gel efficacy information is insufficient to determine if the medication demonstrates any clinically meaningful benefits beyond those provided by other available therapies.

References

1. Purified Cortrophin™ Gel subcutaneous and intramuscular injection [prescribing information]. Baudette, MN: ANI; October 2023.
2. Tran KA, Harrod C, Bourdette DN, et al. Characterization of the clinical evidence supporting repository corticotropin injection for FDA-approved indications. A scoping review. *JAMA Intern Med.* 2022;182(2):206-217.
3. KDIGO 2021 clinical practice guidelines for the management of glomerular diseases. *Kidney Int.* 2021;100:S1-S276. .
4. National Multiple Sclerosis Society. Expert Opinion Paper. National Clinical Advisory Board of the National Multiple Sclerosis Society. Treatment Recommendations for Physicians. Recommendations Regarding Corticosteroids in the Management of Multiple Sclerosis. Available at: http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/ExpOp_Steroids.pdf. Accessed on April 17, 2023.
5. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapses in MS. *Neurology.* 1989;39:969-971.
6. American College of Rheumatology. Clinical Practice Guidelines. Available at: [Clinical Practice Guidelines \(rheumatology.org\)](https://www.rheumatology.org/ClinicalPracticeGuidelines). Accessed on April 17, 2023.
7. Fitzgerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Care Res (Hoboken).* 2020;72(6):744-760.

8. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
9. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019;71(10):1599-1613.
10. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Care Res*. 2016;68:151-166.
11. Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. *Rheumatology*. 2022;61(5):1760-1768.
12. American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. *Diabetes Care*. 2022;45(1):S175-S184.
13. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol*. 2022;74(4):553-569.
14. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDT) recommendations for the management of lupus nephritis. *Ann Rheum Dis*. 2020;79:713-732.
15. Crane AB, Sharon Y, Chu DS. Use of adrenocorticotrophic hormone in ophthalmology. *J Ocul Pharmacol Ther*. 2020;36(9):661-667.
16. Wirta D, McLaurin E, Ousler G, et al. Repository corticotropin injection (Acthar® gel) for refractory severe noninfectious keratitis: efficacy and safety from a phase 4, multicenter, open-label study. *Ophthalmol Ther*. 2021;10:1077-1092.
17. Anesi SD, Chang PY, Maleki A, et al. Treatment of noninfectious retinal vasculitis using subcutaneous repository corticotropin injection. *J Ophthalmic Vis Res*. 2021;16:219-233.
18. Singh JA, Guyatt G, Ordie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2019;71(1):5-32.
19. Fraenkiel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2021;73(7):924-939.
20. Kidney Disease Improving Global Outcomes lupus nephritis work group. KDIGO 2024 clinical practice guidelines for the management of lupus nephritis. *Kidney Int*. 2024;105(Suppl 1S):S1-S69.
21. Kidney Disease Improving Global Outcomes ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. *Kidney Int*. 2024;105(Suppl 3S):S71-S116.